Revolutionizing Dairy Farming: BIOLUMPIVAXIN Vaccine Approved!
In a significant milestone for India’s dairy industry, Biovet, a proud part of Bharat Biotech, has received approval from the Central Drugs Standard Control Organization (CDSCO) for its innovative lumpy skin disease vaccine, BIOLUMPIVAXIN. This breakthrough is not just a win for farmers but an essential step towards a sustainable future in dairy farming.
What is BIOLUMPIVAXIN?
BIOLUMPIVAXIN is a vaccine specifically designed to combat lumpy skin disease (LSD), a viral illness affecting dairy cattle and buffaloes. This vaccine has been developed using a strain sourced from the Indian Council of Agricultural Research – National Research Centre on Equines (ICAR-NRCE). With a production capacity of 500 million doses annually, it promises to be a game-changer for the livestock industry.
The Impact on Dairy Sustainability
Lumpy skin disease can lead to severe economic losses for dairy farmers due to reduced milk production and increased veterinary costs. With the introduction of BIOLUMPIVAXIN, farmers can look forward to healthier cattle, improved milk yield, and reduced mortality rates. This vaccine not only protects the animals but also ensures the sustainability of dairy farming in India.
Join the Movement!
Farmers and dairy producers are encouraged to adopt BIOLUMPIVAXIN as a proactive measure against lumpy skin disease. It’s not just about safeguarding livestock; it’s about embracing a future where dairy farming thrives without the shadow of debilitating diseases.
Get Your Supplies at Looffers.com
For all your agricultural needs and innovative solutions like BIOLUMPIVAXIN, visit Looffers.com. We provide a comprehensive range of products to support your farming endeavors!
In conclusion, the approval of BIOLUMPIVAXIN marks a new dawn for the dairy industry in India. Let’s embrace this innovation to ensure a healthier tomorrow for our cattle and a more sustainable future for our farmers!
